Key facts
- This page summarizes Paul Hopper's Form 4 filing for Scopus BioPharma Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 17 Nov 2021, 08:48.
Paul Hopper - 01 Jun 2021 Form 4 Insider Report for Scopus BioPharma Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 01 Jun 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Nov 2021, 08:48:52 UTC
- Prior SEC filing
- 17 Nov 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Paul Hopper
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Paul Hopper filed Form 4 for Scopus BioPharma Inc. on 17 Nov 2021.
Change
- Previous filing in this sequence was filed on 17 Nov 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SCPS
transaction
Common Stock
Other
- Transaction value
- Shares
- +700,000
- Change %
- Price
- Shares after
- $1,400,000
- Date
- 01 Jun 2021
- Ownership
- By Moreglade Pty. Limited
- Footnotes
- F1, F2
SCPS
transaction
Common Stock
Other
- Transaction value
- Shares
- +6,333
- Change %
- Price
- Shares after
- $12,666
- Date
- 01 Jun 2021
- Ownership
- Direct
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Issued as partial consideration for the sale of Bioscience Oncology Pty. Ltd. to the issuer on June 10, 2020 pursuant to the Conditional Stock Purchase Agreement dated as of June 8, 2020 among the issuer, as purchaser, and Mr. Hopper and the other sellers party thereto, as sellers.
Footnote F2
Mr. Hopper is a director of Moreglade Pty. Limited and therefore is deemed to have shared voting and dispositive power over the shares of Common Stock held by this entity. Mr. Hopper disclaims beneficial ownership of the shares of Common Stock held by this entity, as he has no pecuniary interest therein.
Footnote F3
Excludes 12,666 shares owned by Mr. Hopper's spouse and an aggregate of 101,336 shares owned by Mr. Hopper's adult children, as to which shares he disclaims beneficial ownership.